Aerie pharmaceuticals announces first participant dosed in the phase 3 registrational comet-2 study of ar-15512 for the treatment of dry eye disease

Durham, n.c.--(business wire)--aerie pharmaceuticals, inc. (nasdaq: aeri), a pharmaceutical company focused on the discovery, development, and commercialization of first-in-class ophthalmic therapies, today announced that the first participant has been dosed in the phase 3 registrational “comet-2” study to evaluate ar-15512 ophthalmic solution as a treatment for the signs and symptoms of dry eye disease (ded). comet-2 is the first of three trials in the phase 3 registrational program for ar-155
AERI Ratings Summary
AERI Quant Ranking